AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00617-06v1
50/12/4214    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serrano-Martín, X.
Right arrow Articles by Mendoza-León, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serrano-Martín, X.
Right arrow Articles by Mendoza-León, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2006, p. 4214-4216, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00617-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Glibenclamide, a Blocker of K+ATP Channels, Shows Antileishmanial Activity in Experimental Murine Cutaneous Leishmaniasis{triangledown}

Xenón Serrano-Martín,1 Gilberto Payares,2 and Alexis Mendoza-León1*

Laboratorio de Bioquímica y Biología Molecular de Parásitos,1 Laboratorio de Inmunología y Quimioterapia, Instituto de Biología Experimental (IBE), Facultad de Ciencias, Universidad Central de Venezuela, Apartado 47577, Caracas 1041A, Venezuela2

Received 19 May 2006/ Returned for modification 13 June 2006/ Accepted 23 September 2006

Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.

* Corresponding author. Mailing address: Laboratorio de Bioquímica y Biología Molecular de Parásitos, Instituto de Biología Experimental (IBE), Facultad de Ciencias, Universidad Central de Venezuela, Apartado 47577, Caracas 1041A, Venezuela. Phone and fax: 00 (58) 212 7535897. E-mail: amendoza50{at}cantv.net.

{triangledown} Published ahead of print on 2 October 2006.

Antimicrobial Agents and Chemotherapy, December 2006, p. 4214-4216, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00617-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.